<DOC>
	<DOCNO>NCT01765270</DOCNO>
	<brief_summary>Individuals type 2 diabetes mellitus ( T2DM ) increase risk cardiovascular event ( example , heart attack ) risk relate one 's overall control blood glucose level . In study investigator measure effect saxagliptin , compare placebo , , , coronary artery bypass graft ( CABG ) surgery . The investigator use samples patient ' blood tissue measure evaluate indicator body 's response treatment . This study do evaluate effect saxagliptin biomarkers heart help u understand whether reduce control person 's blood glucose level CABG surgery produce good clinical outcome ( example , good heart health ) .</brief_summary>
	<brief_title>Mechanistic Assessment Properties Saxagliptin Subjects Undergoing Coronary Artery Bypass Graft Surgery</brief_title>
	<detailed_description>This study randomize , double-blind , placebo-controlled clinical trial evaluate effect saxagliptin cardiac biomarkers myocardial necrosis , cardiac function , inflammation , apoptosis subject Type 2 diabetes mellitus ( T2DM ) undergo CABG surgery ( pump , via median sternotomy approach ) integrate measure potential mechanistic effect saxagliptin prevention cardiovascular ( CV ) outcomes . Approximately 74 subject randomize complete study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Known diagnosis type 2 diabetes mellitus ( T2DM ) glycosylated hemoglobin ( HbA1c ) 6.5 % 10 % , inclusive . Stable dos oral antihyperglycemic agent least 2 month Stable dose chronic insulin therapy least 2 month HbA1c document within 3 month study enrollment Planned first elective coronary artery bypass graft ( CABG ) surgery Elevated Creatine KinaseMyocardial Bands ( CKMB ) troponin level 99th percentile screen Receiving incretin therapy receive incretin therapy within previous 2 month Type 1 DM history ketoacidosis Women pregnant breastfeed Known endstage Kidney disease Known sensitivity intolerance saxagliptin dipeptidyl peptidase4 ( DPP4 ) inhibitor Clinically apparent liver disease History pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Coronary Artery Bypass Surgery</keyword>
</DOC>